In a report released yesterday, Chris Cooley from Stephens reiterated a Buy rating on Sientra (NASDAQ: SIEN), with a price target of $30. The company’s shares closed yesterday at $21.78.
According to TipRanks.com, Cooley is a 5-star analyst with an average return of 34.4% and a 75.0% success rate. Cooley covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Staar Surgical Company, and DENTSPLY SIRONA Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sientra with a $25.75 average price target, a 18.2% upside from current levels. In a report released yesterday, Stifel Nicolaus also maintained a Buy rating on the stock with a $25 price target.
.
See today’s analyst top recommended stocks >>
Based on Sientra’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $18.03 million. In comparison, last year the company had a GAAP net loss of $20.39 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sientra, Inc. operates as a medical aesthetics company, which engages in developing and commercializing plastic surgery implantable devices. Its products include breast implants, breast tissue expanders, silicone scar treatment, and additional tissue expanders. The company was founded by Hani M. Zeini in 2006 and is headquartered in Santa Barbara, CA.
